试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-29
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
编号:NCT05501912登记状态:提前终止企业 / 申办者:ABM Therapeutics Shanghai Company Limited
药物 / 成分:ABM-1310
登记的停止原因(原文):Adjustment of the applicant's research and development strategy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-29
A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors
编号:NCT05892653登记状态:提前终止企业 / 申办者:ABM Therapeutics Shanghai Company Limited
药物 / 成分:ABM-1310
登记的停止原因(原文):Adjustment of the applicant's research and development strategy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
Cyclobenzaprine Extended Release (ER) for Fibromyalgia
编号:NCT01041495登记状态:提前终止企业 / 申办者:State University of New York - Upstate Medical University
药物 / 成分:cyclobenzaprine ER (AMRIX)、placebo
登记的停止原因(原文):ran out of funding short of enrollment expected
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
编号:NCT02495233登记状态:提前终止企业 / 申办者:Astellas Pharma Global Development, Inc.
药物 / 成分:Gilteritinib、Erlotinib
登记的停止原因(原文):Study terminated due to adverse events related to the combination therapy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
编号:NCT02891161登记状态:提前终止企业 / 申办者:Monika Joshi, MD
药物 / 成分:durvalumab、Radiation Therapy
登记的停止原因(原文):Sponsor-investigator elected to discontinue followup on remaining subjects after planned analyses and manuscripts were completed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
编号:NCT03954041登记状态:提前终止企业 / 申办者:Remedy Pharmaceuticals, Inc.
药物 / 成分:BIIB093、Placebo
登记的停止原因(原文):Early completed due to strategic considerations, not for efficacy or safety reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
编号:NCT04493333登记状态:提前终止企业 / 申办者:University of Arkansas
药物 / 成分:Vaginal Dehydroepiandrosterone、Vaginal Polycarbophil Moisturizer
登记的停止原因(原文):Low recruitment/enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
编号:NCT04656275登记状态:提前终止企业 / 申办者:Boehringer Ingelheim
药物 / 成分:BI 1323495、Placebo
登记的停止原因(原文):Company decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
编号:NCT04755244登记状态:提前终止企业 / 申办者:ALX Oncology Inc.
药物 / 成分:evorpacept、venetoclax、azacitidine
登记的停止原因(原文):While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
编号:NCT05511519登记状态:提前终止企业 / 申办者:Aclaris Therapeutics, Inc.
药物 / 成分:ATI-450、Placebo Oral Tablet
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗